Lmr Partners LLP Bluebird Bio, Inc. Transaction History

Lmr Partners LLP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$18.04 - $22.09 $938,458 - $1.15 Million	-52,021 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$16.59 - $33.89 $863,028 - $1.76 Million	52,021 New	52,021 $1.57 Million
Q2 2020 Aug 14, 2020	SELL	$27.12 - $45.97 $171,479 - $290,668	-6,323 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$26.16 - $63.5 $248,127 - $602,297	-9,485 Reduced 60.0%	6,323 $297,000
Q2 2019 Aug 14, 2019	SELL	$75.84 - $105.21 $318,300 - $441,566	-4,197 Reduced 20.98%	15,808 $2.01 Million
Q1 2019 May 15, 2019	BUY	$64.44 - $104.11 $1.29 Million - $2.08 Million	20,005 New	20,005 $3.15 Million
Q4 2018 Feb 14, 2019	SELL	$59.1 - $93.26 $187,051 - $295,167	-3,165 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$88.86 - $117.49 $5.34 Million - $7.06 Million	-60,127 Reduced 95.0%	3,165 $462,000
Q2 2018 Aug 03, 2018	BUY	$99.64 - $127.59 $6.31 Million - $8.08 Million	63,292 New	63,292 $9.93 Million

112

61.5M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $485M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Lmr Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Lmr Partners LLP with notifications on news.